ACET Adicet Bio, Inc. - Common Stock
$9,34
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$0–$10
95% of range
Analystenbewertung
BUY
12 analysts
Kursziel
$33
+255% upside
P/E (TTM)
-0.5
ROE
—
Nettogewinnmarge
—
ACET Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$9.34
Marktkapitalisierung
—
P/E (TTM)
-0.5
EPS (TTM)
$-16.95
Umsatz (TTM)
—
Dividendenrendite
—
ROE
—
Verschuldungsgrad
—
52W-Spanne
$0 – $10
ACET Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
—
EPS
$-16.95
2021-12-31
→
2025-12-31
Freier Cashflow
—
2018-12-31
→
2024-12-31
Margen
—
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
ACET
Peer-Median
P/E (TTM)
-0.5
2.6
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
ACET
Peer-Median
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
ACET
Peer-Median
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
ACET
Peer-Median
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
ACET
Peer-Median
ACET Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
12 Analysten
- Starker Kauf 5 41,7%
- Kauf 6 50,0%
- Halten 1 8,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
6 Analysten · 2026-08-19
Median
$22.50
Mittelwert
$33.17
← Unter allen Zielen
$9.34
Tief
$18.00
Hoch
$90.00
Median-Ziel
$22.50
+141,0%
Mittelwert-Ziel
$33.17
+255,3%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.23%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-1.99 | $-2.07 | 0.08% |
| 31. März 2026 | $-1.88 | $-3.17 | 1.3% |
| 31. Dezember 2025 | $-2.94 | $-2.86 | -0.08% |
| 30. September 2025 | $-4.64 | $-4.73 | 0.09% |
| 30. Juni 2025 | $-5.44 | $-4.97 | -0.47% |
| 31. März 2025 | $-4.96 | $-5.41 | 0.45% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ACET | — | -0.5 | — | — | — | — |
| ICCC | — | -51.2 | 4.3% | — | — | — |
| KLRS | $193M | -3.0 | — | — | -65.8% | — |
| ACRV | $76M | -1.2 | — | — | -61.0% | — |
| ATRA | $132M | 7.0 | -6.3% | 27.1% | -88.9% | — |
| SERA | — | -4.4 | 5.2% | -39417.3% | -39.0% | — |
| ELTX | — | -3.1 | — | — | — | — |
| FRMM | — | — | — | -6881.3% | -368.1% | — |
| ANVS | $94M | -2.5 | — | — | -164.0% | — |
| CYPH | $97M | 16.6 | — | — | 6.1% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $99M | $99M | $106M | $71M | $49M | $34M | $24M | $15M | $17M | |
| SG&A Expense | $23M | $28M | $27M | $26M | $22M | $23M | $9M | $8M | $2M | |
| Operating Expenses | $122M | $128M | $152M | $98M | $71M | $57M | $32M | $23M | $19M | |
| Operating Income | $-122M | $-128M | $-152M | $-73M | $-61M | $-39M | $-31M | $-15M | $-19M | |
| Interest Expense | $36.0K | $4.0K | $25.0K | $80.0K | $176.0K | $134.0K | · | · | · | |
| Interest Income | $6M | $11M | $10M | · | · | · | · | · | · | |
| Other Non-op | $-430.0K | $-217.0K | $-573.0K | $-919.0K | $-606.0K | $-953.0K | $2M | $5M | $-15M | |
| Pretax Income | $-117M | $-117M | $-143M | $-70M | $-62M | $-39M | $-28M | $-10M | $-34M | |
| Income Tax | $0 | $0 | $0 | $0 | $-125.0K | $-3M | $19.0K | $-589.0K | $0 | |
| Net Income | $-117M | $-117M | $-143M | $-70M | $-62M | $-37M | $-28M | $-9M | $-34M | |
| EPS (Basic) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | · | · | · | · | |
| EPS (Diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | · | · | · | · | |
| Shares (Basic) | 6,891,336 | 5,491,652 | 43,042,405 | 41,080,286 | 30,952,152 | 7,319,977 | 2,148,317 | 2,049,680 | · | |
| Shares (Diluted) | 6,891,336 | 5,491,652 | 43,042,405 | 41,080,286 | 30,952,152 | · | · | · | · | |
| EBITDA | · | $-128M | $-152M | $-73M | $-61M | · | $-85M | $-40M | · |
Bilanz 26
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $56M | $160M | $258M | $278M | $84M | $11M | $9M | $53M | |
| Short-term Investments | · | · | $0 | · | · | · | · | · | $0 | |
| Prepaid Expense | $2M | $4M | $3M | $3M | $5M | $6M | $2M | $1M | $792.0K | |
| Other Current Assets | $314.0K | $737.0K | $457.0K | $336.0K | $2.0K | $229.0K | $179.0K | $15.0K | $84.0K | |
| Current Assets | $161M | $180M | $162M | $261M | $282M | $100M | $64M | $110M | $55M | |
| PP&E (Net) | $17M | $23M | $27M | $29M | $15M | $3M | $2M | $321.0K | $39.0K | |
| PP&E (Gross) | $44M | $44M | $42M | $37M | $21M | $8M | $6M | $406.0K | $44.0K | |
| Accum. Depreciation | $27M | $21M | $15M | $9M | $6M | $5M | $4M | $85.0K | $5.0K | |
| Goodwill | · | · | $0 | $19M | $19M | $20M | · | · | · | |
| Intangibles | · | · | · | · | $0 | · | · | · | · | |
| Other Non-current Assets | $76.0K | $428.0K | $822.0K | $1M | $2M | $2M | $410.0K | · | · | |
| Total Assets | $192M | $220M | $207M | $331M | $339M | $154M | $82M | $110M | $55M | |
| Accounts Payable | $5M | $5M | $3M | $4M | $3M | $2M | $1M | $3M | $2M | |
| Accrued Liabilities | · | · | · | · | · | · | $5M | $3M | $4M | |
| Current Liabilities | $22M | $19M | $19M | $20M | $16M | $22M | $15M | $6M | $6M | |
| Capital Leases | $11M | $14M | $18M | $19M | $19M | $20M | · | · | · | |
| Deferred Tax | · | · | · | · | · | $125.0K | · | · | · | |
| Other Non-current Liabilities | $62.0K | $116.0K | $130.0K | $114.0K | $115.0K | · | $15.0K | $19.0K | · | |
| Total Liabilities | $33M | $34M | $37M | $38M | $36M | $44M | $28M | $6M | $6M | |
| Common Stock | $10.0K | $5.0K | $4.0K | $4.0K | $4.0K | $2.0K | $4.0K | $3.0K | $1.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | $176M | $2M | |
| Retained Earnings | $-615M | $-498M | $-381M | $-238M | $-168M | $-106M | $-70M | $-71M | $-34M | |
| AOCI | $102.0K | $16.0K | $0 | $0 | $0 | $24.0K | $23.0K | $-41.0K | · | |
| Stockholders' Equity | $159M | $187M | $170M | $292M | $303M | $110M | $-60M | $-34M | $-27M | |
| Liabilities + Equity | $192M | $220M | $207M | $331M | $339M | $154M | $82M | $110M | $55M | |
| Shares Outstanding | 9,586,770 | 5,160,545 | 43,270,386 | 42,954,820 | 39,736,914 | 39,736,914 | 2,155,578 | 28,055,344 | 5,659,089 |
Cashflow 12
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $3M | $2M | $1M | $1M | $1M | $5.0K | |
| Stock-based Comp | $14M | $22M | $20M | $17M | $13M | $5M | $1M | $2M | $470.0K | |
| Deferred Tax | $0 | $0 | $0 | $0 | $-125.0K | $-242.0K | · | · | · | |
| Operating Cash Flow | $-95M | $-92M | $-94M | $-45M | $-51M | $-42M | $-28M | $-18M | $-11M | |
| CapEx | $2M | $1M | $4M | $17M | $13M | $990.0K | $1M | $876.0K | $44.0K | |
| Investing Cash Flow | $2M | $-119M | $-4M | $-17M | $-3M | $115M | $-48M | $-16M | $-44.0K | |
| Stock Issued | $0 | $19M | $0 | $43M | $238M | · | · | · | · | |
| Net Stock Activity | · | $19M | $0 | $0 | $238M | · | · | · | · | |
| Financing Cash Flow | $75M | $111M | $236.0K | $42M | $243M | $303.0K | $77M | $11M | $64M | |
| Net Change in Cash | $-18M | $-100M | $-98M | $-20M | $189M | $74M | $1M | $-23M | $53M | |
| Free Cash Flow | · | $-93M | $-98M | $-62M | $-64M | · | $-74M | $-36M | · | |
| Levered FCF | · | $-94M | $-98M | $-62M | $-64M | · | · | · | · |
Rentabilität 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROA | · | -54.8% | -53.0% | -20.8% | -25.2% | · | -81.2% | -45.6% | · | |
| ROE | · | -58.8% | -78.2% | -22.9% | -23.8% | · | -600.2% | -35.2% | · | |
| ROIC | · | -68.4% | -89.3% | -24.8% | -20.2% | · | -104.7% | -38.1% | · |
Liquidität & Solvenz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 9.3 | 8.4 | 13.2 | 17.3 | · | 7.6 | 19.2 | · | |
| Quick Ratio | · | 2.9 | 8.3 | 13.1 | 17.0 | · | 2.8 | 1.2 | · | |
| Interest Coverage | · | -31903.8 | -6081.5 | -906.9 | -349.1 | · | · | · | · |
Bewertung (TTM) 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-117M | $-117M | $-143M | $-70M | $-62M | $-37M | $-28M | $-9M | $-34M | |
| Market Cap | · | $79M | $82M | $355M | $695M | · | $380M | $1.69B | · | |
| P/E | -0.5 | -0.0 | -0.6 | -5.3 | -8.7 | · | · | · | · | |
| P/B | · | 0.4 | 0.5 | 1.2 | 2.3 | · | 4.7 | 16.2 | · | |
| P / Tangible Book | 0.5 | 0.4 | 0.5 | 1.3 | 2.5 | 3.1 | · | · | · | |
| P / Cash Flow | · | -0.9 | -0.9 | -7.9 | -13.6 | · | -5.2 | -47.6 | · | |
| P / FCF | · | -0.8 | -0.8 | -5.8 | -10.8 | · | -5.1 | -47.2 | · | |
| Earnings Yield | -201.3% | -2217.3% | -175.1% | -19.0% | -11.4% | · | · | · | · |
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $18M | $17M | $25M | $23M | $28M | $23M | $23M | $26M | $26M | $24M | $25M | $26M | $28M | $27M | $25M | $17M | |
| SG&A Expense | $4M | $4M | $7M | $5M | $4M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $6M | |
| Operating Expenses | $22M | $22M | $32M | $28M | $32M | $30M | $31M | $33M | $33M | $31M | $32M | $52M | $35M | $33M | $32M | $23M | |
| Operating Income | $-22M | $-22M | $-32M | $-28M | $-32M | $-30M | $-31M | $-33M | $-33M | $-31M | $-32M | $-52M | $-35M | $-33M | $-32M | $-23M | |
| Interest Expense | $22.0K | $23.0K | $24.0K | $12.0K | $0 | $0 | $1.0K | $1.0K | $0 | $2.0K | $1.0K | $1.0K | $4.0K | $19.0K | $26.0K | $18.0K | |
| Interest Income | $1M | $1M | $2M | $1M | $1M | $2M | $2M | $3M | $3M | $3M | · | · | · | · | · | · | |
| Other Non-op | $-60.0K | $7.0K | $-131.0K | $-64.0K | $-223.0K | $-12.0K | $-51.0K | $-54.0K | $-51.0K | $-61.0K | $-101.0K | $-142.0K | $-124.0K | $-206.0K | $-462.0K | $-217.0K | |
| Pretax Income | $-21M | $-20M | $-31M | $-27M | $-31M | $-28M | $-29M | $-30M | $-30M | $-28M | $-29M | $-50M | $-32M | $-31M | $-30M | $-22M | |
| Income Tax | $143.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | |
| Net Income | $-21M | $-20M | $-31M | $-27M | $-31M | $-28M | $-29M | $-30M | $-30M | $-28M | $-29M | $-50M | $-32M | $-31M | $-30M | $-22M | |
| EPS (Basic) | $-1.99 | $-1.88 | $-16.01 | $-0.29 | $-5.48 | $-4.96 | $-20.31 | $-0.34 | $-0.33 | $-0.35 | $-0.68 | $-1.16 | $-0.75 | $-0.72 | $-0.73 | $-0.53 | |
| EPS (Diluted) | $-1.99 | $-1.88 | $-16.01 | $-0.29 | $-5.48 | $-4.96 | $-20.31 | $-0.34 | $-0.33 | $-0.35 | $-0.68 | $-1.16 | $-0.75 | $-0.72 | $-0.71 | $-0.53 | |
| Shares (Basic) | 10,745,553 | 10,744,621 | -266,352,070 | 91,086,464 | 5,692,816 | 5,691,965 | -255,058,338 | 90,846,293 | 90,632,045 | 79,071,652 | -85,850,959 | 42,980,641 | 42,957,035 | 42,955,688 | -80,460,835 | 41,642,815 | |
| Shares (Diluted) | 10,745,553 | 10,744,621 | -266,352,070 | 91,086,464 | 5,692,816 | 5,691,965 | -255,058,338 | 90,846,293 | 90,632,045 | 79,071,652 | -85,850,959 | 42,980,641 | 42,957,035 | 42,955,688 | -86,596,530 | 41,642,815 | |
| EBITDA | $-22M | $-22M | · | $-28M | $-32M | $-30M | · | $-33M | $-33M | $-31M | · | $-52M | $-35M | $-33M | · | $-23M |
Bilanz 22
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33M | $36M | $39M | $29M | $35M | $28M | $56M | $105M | $224M | $248M | $160M | $183M | $205M | $232M | $258M | $283M | |
| Short-term Investments | · | · | · | · | · | · | · | $97M | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Other Current Assets | $441.0K | $348.0K | $320.0K | $619.0K | $690.0K | $478.0K | $737.0K | $543.0K | $409.0K | $613.0K | $457.0K | $378.0K | $489.0K | $511.0K | $336.0K | $380.0K | |
| Current Assets | $121M | $140M | $161M | $106M | $128M | $154M | $180M | $206M | $228M | $250M | $162M | $186M | $209M | $235M | $261M | $286M | |
| PP&E (Net) | $14M | $15M | $17M | $18M | $20M | $21M | $23M | $24M | $24M | $25M | $27M | $28M | $30M | $30M | $29M | $27M | |
| PP&E (Gross) | $44M | $44M | $44M | $44M | $44M | $44M | $44M | $44M | $42M | $42M | $42M | $41M | $41M | $40M | $37M | $35M | |
| Accum. Depreciation | $30M | $29M | $27M | $26M | $24M | $23M | $21M | $20M | $18M | $16M | $15M | $13M | $12M | $10M | $9M | $8M | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | · | $0 | $19M | $19M | $19M | $19M | |
| Other Non-current Assets | $80.0K | $78.0K | $76.0K | $110.0K | $225.0K | $314.0K | $428.0K | $508.0K | $593.0K | $691.0K | $822.0K | $916.0K | $1M | $1M | $1M | $1M | |
| Total Assets | $148M | $169M | $192M | $140M | $163M | $191M | $220M | $246M | $269M | $293M | $207M | $233M | $278M | $305M | $331M | $354M | |
| Accounts Payable | $4M | $3M | $5M | $4M | $3M | $4M | $5M | $2M | $2M | $3M | $3M | $4M | $3M | $3M | $4M | $5M | |
| Current Liabilities | $18M | $18M | $22M | $19M | $17M | $16M | $19M | $19M | $18M | $17M | $19M | $20M | $19M | $18M | $20M | $17M | |
| Capital Leases | $9M | $10M | $11M | $12M | $12M | $13M | $14M | $15M | $16M | $17M | $18M | $19M | $20M | $21M | $19M | $19M | |
| Other Non-current Liabilities | $0 | $0 | $62.0K | $125.0K | $116.0K | $116.0K | $116.0K | $116.0K | $116.0K | $116.0K | $130.0K | $143.0K | $130.0K | $116.0K | $114.0K | $116.0K | |
| Total Liabilities | $28M | $29M | $33M | $31M | $30M | $30M | $34M | $34M | $34M | $34M | $37M | $39M | $39M | $39M | $38M | $37M | |
| Common Stock | $1.0K | $1.0K | $10.0K | $8.0K | $8.0K | $8.0K | $5.0K | $8.0K | $8.0K | $8.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-656M | $-635M | $-615M | $-584M | $-557M | $-526M | $-498M | $-469M | $-439M | $-409M | $-381M | $-351M | $-301M | $-269M | $-238M | $-208M | |
| AOCI | $-105.0K | $-37.0K | $102.0K | $56.0K | $-41.0K | $-9.0K | $16.0K | $121.0K | · | · | $0 | · | $0 | $0 | · | $0 | |
| Stockholders' Equity | $120M | $140M | $159M | $109M | $133M | $161M | $187M | $212M | $235M | $259M | $170M | $195M | $239M | $266M | $292M | $318M | |
| Liabilities + Equity | $148M | $169M | $192M | $140M | $163M | $191M | $220M | $246M | $269M | $293M | $207M | $233M | $278M | $305M | $331M | $354M | |
| Shares Outstanding | 9,361,371 | 9,597,693 | 9,586,770 | 83,253,779 | 83,252,520 | 82,709,625 | 5,160,545 | 82,400,960 | 82,400,960 | 82,169,503 | 43,270,386 | 43,107,921 | 43,066,158 | 42,957,431 | 42,954,820 | 42,787,657 |
Cashflow 11
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $800.0K | |
| Stock-based Comp | $1M | $1M | $6M | $2M | $3M | $3M | $4M | $7M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | |
| Operating Cash Flow | $-20M | $-21M | $-21M | $-22M | $-27M | $-25M | $-24M | $-22M | $-23M | $-23M | $-23M | $-21M | $-25M | $-24M | $-19M | $-15M | |
| CapEx | $202.0K | $37.0K | $-10.0K | $209.0K | $47.0K | $1M | $176.0K | $401.0K | $302.0K | $239.0K | $136.0K | $906.0K | $2M | $2M | $6M | $5M | |
| Investing Cash Flow | $17M | $19M | $-45M | $17M | $33M | $-3M | $-22M | $-97M | $-302.0K | $-239.0K | $-136.0K | $-906.0K | $-2M | $-2M | $-6M | $-5M | |
| Stock Issued | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $19M | $0 | $0 | $0 | $0 | $0 | $43M | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $19M | · | · | · | · | · | · | |
| Financing Cash Flow | $58.0K | $-65.0K | $75M | $-150.0K | $267.0K | $-104.0K | $137.0K | $0 | $204.0K | $111M | $76.0K | $-59.0K | $226.0K | $-7.0K | $304.0K | $42M | |
| Net Change in Cash | $-3M | $-3M | $10M | $-6M | $7M | $-28M | $-46M | $-119M | $-24M | $88M | $-24M | $-22M | $-26M | $-26M | $-25M | $22M | |
| Free Cash Flow | · | $-22M | · | · | · | $-27M | · | · | · | $-23M | · | · | · | $-26M | · | · | |
| Levered FCF | · | $-22M | · | · | · | $-27M | · | · | · | $-23M | · | · | · | $-26M | · | · |
Rentabilität 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -13.7% | -11.2% | · | -13.9% | -14.5% | -11.7% | · | -12.7% | -10.9% | -9.4% | · | -17.0% | -10.7% | -9.6% | · | -7.2% | |
| ROE | -16.9% | -13.4% | · | -16.8% | -16.9% | -13.4% | · | -15.0% | -12.6% | -10.7% | · | -19.5% | -12.2% | -10.7% | · | -8.2% | |
| ROIC | -18.7% | -15.4% | · | -25.6% | -24.3% | -18.5% | · | -15.7% | · | -11.9% | · | -26.9% | -14.6% | -12.5% | · | -7.2% |
Liquidität & Solvenz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 7.7 | · | 5.6 | 7.5 | 9.3 | · | 10.6 | 12.8 | 14.3 | · | 9.4 | 11.1 | 13.0 | · | 16.6 | |
| Quick Ratio | 1.8 | 2.0 | · | 1.5 | 2.0 | 1.7 | · | 10.4 | 12.5 | 14.2 | · | 9.3 | 10.9 | 12.8 | · | 16.4 | |
| Interest Coverage | -1013.7 | -937.8 | · | -2329.3 | · | · | · | -33153.0 | · | -15435.5 | · | -52262.0 | -8722.5 | -1753.8 | · | -1276.9 |
Bewertung (TTM) 8
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-100M | $-107M | · | $-117M | $-120M | $-117M | · | $-138M | $-140M | $-141M | · | $-135M | $-108M | $-71M | · | $-54M | |
| Market Cap | $81M | $65M | · | $67M | $51M | $62M | · | $119M | $100M | $193M | · | $59M | $105M | $247M | · | $608M | |
| P/E | -0.9 | -0.9 | · | -0.6 | -0.5 | -0.6 | · | -0.7 | -0.5 | -0.8 | · | -0.4 | -0.9 | -3.4 | · | -9.9 | |
| P/B | 0.7 | 0.5 | · | 0.6 | 0.4 | 0.4 | · | 0.6 | 0.4 | 0.7 | · | 0.3 | 0.4 | 0.9 | · | 1.9 | |
| P / Tangible Book | 0.7 | 0.5 | · | 0.6 | 0.4 | 0.4 | · | 0.6 | 0.4 | 0.7 | · | 0.3 | 0.5 | 1.0 | · | 2.0 | |
| P / Cash Flow | · | -3.0 | · | · | · | -2.5 | · | · | · | -8.5 | · | · | · | -10.3 | · | · | |
| P / FCF | · | -3.0 | · | · | · | -2.3 | · | · | · | -8.4 | · | · | · | -9.5 | · | · | |
| Earnings Yield | -111.6% | -109.7% | · | -158.0% | -216.4% | -176.2% | · | -151.4% | -214.0% | -126.8% | · | -230.7% | -105.4% | -29.7% | · | -10.1% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Nettoergebnis | $-117M | $-117M | $-143M | $-70M | $-62M |
| Verwässerte EPS | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | — | 9.3 | 8.4 | 13.2 | 17.3 |
| Quick Ratio | — | 2.9 | 8.3 | 13.1 | 17.0 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | — | $-93M | $-98M | $-62M | $-64M |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 62 Einreicher · $55.5M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 20 (+10 vs. Vorquartal) | 6 (-4 vs. Vorquartal) | 14 (+1 vs. Vorquartal) | 10 (+3 vs. Vorquartal) | -34K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $8.057.871 | 932.624 | 14,52% | Aktien |
| ORBIMED ADVISORS LLC | $7.298.960 | 844.787 | 13,15% | Aktien |
| FRANKLIN RESOURCES INC | $5.413.573 | 626.571 | 9,75% | Aktien |
| CITADEL ADVISORS LLC | $3.738.856 | 432.738 | 6,74% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.965.490 | 343.228 | 5,34% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.370.600 | 274.375 | 4,27% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $2.297.765 | 265.945 | 4,14% | Aktien |
| Stonepine Capital Management, LLC | $2.121.276 | 245.518 | 3,82% | Aktien |
| VANGUARD GROUP INC | $1.984.779 | 235.722 | 3,58% | Aktien |
| Aquilo Capital Management, LLC | $1.854.426 | 2.456.194 | 3,34% | Aktien |
| Alyeska Investment Group, L.P. | $1.760.823 | 203.799 | 3,17% | Aktien |
| Schonfeld Strategic Advisors LLC | $1.689.238 | 195.514 | 3,04% | Aktien |
| Carlyle Group Inc. | $1.592.308 | 184.295 | 2,87% | Aktien |
| NEXTBio Capital Management LP | $1.363.625 | 157.827 | 2,46% | Aktien |
| TWO SIGMA ADVISERS, LP | $937.449 | 111.336 | 1,69% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $836.689 | 96.839 | 1,51% | Aktien |
| DAFNA Capital Management LLC | $810.536 | 93.812 | 1,46% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $742.686 | 85.959 | 1,34% | Aktien |
| Trexquant Investment LP | $673.937 | 78.002 | 1,21% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $664.591 | 76.871 | 1,20% | Aktien |
| Burkehill Global Management, LP | $540.000 | 62.500 | 0,97% | Aktien |
| REGENERON PHARMACEUTICALS, INC. | $522.819 | 60.511 | 0,94% | Aktien |
| JANE STREET GROUP, LLC | $448.131 | 51.867 | 0,81% | Aktien |
| Rangeley Capital, LLC | $439.707 | 50.892 | 0,79% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $437.789 | 50.670 | 0,79% | Aktien |
| RBF Capital, LLC | $333.348 | 38.582 | 0,60% | Aktien |
| STATE STREET CORP | $312.958 | 36.222 | 0,56% | Aktien |
| Quadrature Capital Ltd | $312.708 | 36.193 | 0,56% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $265.956 | 30.782 | 0,48% | Aktien |
| UBS Group AG | $238.905 | 27.651 | 0,43% | Aktien |
| Verdad Advisers, LP | $217.728 | 25.200 | 0,39% | Aktien |
| XTX Topco Ltd | $209.814 | 24.284 | 0,38% | Aktien |
| CITADEL ADVISORS LLC | $196.992 | 22.800 | 0,35% | Verkaufsoption |
| JOHNSON & JOHNSON | $196.811 | 22.779 | 0,35% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $178.416 | 20.650 | 0,32% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $169.344 | 19.600 | 0,31% | Verkaufsoption |
| PRELUDE CAPITAL MANAGEMENT, LLC | $160.272 | 18.550 | 0,29% | Aktien |
| NORTHERN TRUST CORP | $159.287 | 18.436 | 0,29% | Aktien |
| OCCUDO QUANTITATIVE STRATEGIES LP | $143.735 | 16.636 | 0,26% | Aktien |
| Squarepoint Ops LLC | $131.795 | 15.254 | 0,24% | Aktien |
| Vontobel Holding Ltd. | $119.025 | 13.776 | 0,21% | Aktien |
| MARSHALL WACE, LLP | $111.921 | 12.954 | 0,20% | Aktien |
| AXQ CAPITAL, LP | $94.962 | 10.991 | 0,17% | Aktien |
| Jump Financial, LLC | $94.539 | 10.942 | 0,17% | Aktien |
| CITADEL ADVISORS LLC | $92.534 | 10.710 | 0,17% | Kaufoption |
| Arax Advisory Partners | $51.840 | 6.000 | 0,09% | Aktien |
| Vanguard Global Advisers, LLC | $45.109 | 5.221 | 0,08% | Aktien |
| SIMPLEX TRADING, LLC | $41.592 | 4.814 | 0,07% | Aktien |
| MORGAN STANLEY | $18.680 | 2.162 | 0,03% | Aktien |
| ROYAL BANK OF CANADA | $15.000 | 1.687 | 0,03% | Aktien |
| BlackRock, Inc. | $13.833 | 1.601 | 0,02% | Aktien |
| Tower Research Capital LLC (TRC) | $2.393 | 277 | 0,00% | Aktien |
| JPMORGAN CHASE & CO | $1.609 | 188 | 0,00% | Aktien |
| ACADIAN ASSET MANAGEMENT LLC | $1.076 | 124.832 | 0,00% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $432 | 50 | 0,00% | Aktien |
| Caitong International Asset Management Co., Ltd | $406 | 47 | 0,00% | Aktien |
| SBI Securities Co., Ltd. | $207 | 24 | 0,00% | Aktien |
| NATIONAL BANK OF CANADA /FI/ | $146 | 17 | 0,00% | Aktien |
| FMR LLC | $52 | 6 | 0,00% | Aktien |
| TD Waterhouse Canada Inc. | $26 | 3 | 0,00% | Aktien |
| DANSKE BANK A/S | $9 | 1 | 0,00% | Aktien |
| Avion Wealth | $2 | 246 | 0,00% | Aktien |
Unternehmensinsider 28 Insider · 10 Führungskräfte · 14 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Chen Schor | President & CEO | 19. Juni 2026 A | 6.820 | 0 | 0 | $0 |
| Brian Nicholas Harvey | Chief Financial Officer | 24. Januar 2026 F | 5.145 | 0 | 0 | $0 |
| Blake Aftab | Chief Scientific Officer | 19. Juni 2026 A | 2.981 | 0 | 0 | $0 |
| Don Healey | Chief Technology Officer | 24. Januar 2026 F | 3.452 | 0 | 0 | $0 |
| Julia D. Maltzman | Chief Medical Officer | 31. Januar 2025 A | — | 0 | 0 | $0 |
| Francesco Galimi | SVP & Chief Medical Officer | 5. Juni 2024 A | 101.801 | 0 | 0 | $0 |
| Carrie Krehlik | Chief Human Resources Officer | 12. Februar 2021 A | — | 0 | 0 | $0 |
| Joan Mannick | Chief Medical Officer | 6. Dezember 2019 A | 1.404.585 | 0 | 0 | $0 |
| John J Mccabe | Vice President, Finance | 6. Dezember 2019 A | 12.867 | 0 | 0 | $0 |
| Meredith Manning | Chief Commercial Officer | 27. Februar 2019 A | — | 0 | 0 | $0 |
| Katie Peng | Direktor | 21. Juni 2026 A | 11.800 | 0 | 0 | $0 |
| Andrew Sinclair | Direktor | 21. Juni 2026 A | 17.700 | 0 | 0 | $0 |
| Michael Grissinger | Direktor | 21. Juni 2026 A | — | 0 | 0 | $0 |
| Jeffrey Chodakewitz | Direktor | 21. Juni 2026 A | 17.700 | 0 | 0 | $0 |
| Steve Dubin | Direktor | 21. Juni 2026 A | 22.700 | 0 | 0 | $0 |
| Aya Jakobovits | Direktor | 21. August 2024 A | 11.800 | 0 | 0 | $0 |
| Michael Kauffman | Direktor | 21. August 2024 A | 5.900 | 0 | 0 | $0 |
| GORDON CARL L | Direktor | 21. August 2024 A | 11.800 | 0 | 0 | $0 |
| Bastiano Sanna | Direktor | 14. August 2023 A | 5.900 | 0 | 0 | $0 |
| CHIMOVITS EREZ | Direktor | 12. Februar 2021 A | 396.657 | 0 | 0 | $0 |
| David Adam Steinberg | Direktor | 3. Juni 2020 A | — | 0 | 0 | $0 |
| Paul R. Fonteyne | Direktor | 3. Juni 2020 A | — | 0 | 0 | $0 |
| Jonathan Silverstein | Direktor | 3. Juni 2020 A | 4.830.387 | 0 | 0 | $0 |
| PureTech Health LLC | 10%-Eigentümer | 18. Dezember 2019 S | 2.119.696 | 0 | 0 | $0 |
| Lloyd Klickstein | — | 5. August 2026 A | 108.566 | 0 | 0 | $0 |
| Stewart Abbot | — | 11. Juni 2021 A | — | 0 | 0 | $0 |
| Yair Chaim Schindel | — | 17. September 2020 A | 1.104.460 | 0 | 0 | $0 |
| Lynne Marie Sullivan | — | 3. Juni 2020 A | — | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 7 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VI LLC, ORBIMED CAPITAL GP V LLC, OrbiMed Genesis GP LLC, ORBIMED ADVISORS ISRAEL II LTD, ORBIMED ISRAEL GP II, L.P., ORBIMED ISRAEL GP LTD., ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP ×10 Einreichungen | 10. April 2026 | 8,80% | Änderung | — | SEC |
| The Carlyle Group Inc., Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, L.L.C., Carlyle Investment Management L.L.C., Carlyle Genesis UK LLC, Abingworth LLP, Abingworth Bioventures 8 LP ×2 Einreichungen | 7. Februar 2024 | — | Erste Einreichung | — | SEC |
| Abingworth LLP, Abingworth Bioventures 8, LP ×2 Einreichungen | 16. März 2021 | — | Erste Einreichung | — | SEC |
| aMoon Growth Fund Limited Partnership (f/k/a aMoon 2 Fund Limited Partnership), aMoon Growth Fund G.P. Limited Partnership (f/k/a aMoon 2 Fund G.P. Limited Partnership), aMoon General Partner Ltd., Dr. Yair C. Schindel | 18. Februar 2021 | — | Erste Einreichung | — | SEC |
| aMoon 2 Fund Limited Partnership, aMoon 2 Fund G.P. Limited Partnership, aMoon General Partner Ltd., Dr. Yair C. Schindel ×2 Einreichungen | 3. Dezember 2020 | — | Erste Einreichung | — | SEC |
| Adicet Bio, Inc. | 8. Mai 2020 | — | Erste Einreichung | M&A / Verkauf | SEC |
| PureTech Health LLC, PureTech Health plc ×3 Einreichungen | 5. Mai 2020 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 4 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.